Q-omics provides the consensus-scored TOMM5 profile across patient tissues and cancer cell-line models. TOMM5 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TOMM5 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, TOMM5 protein abundance shows 22,352 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, COAD, and PDAC as cancer lineages where TOMM5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TOMM5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TOMM5 survival associations across molecular data types. TOMM5 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TOMM5 RNA expression–survival associations across cancer types. High TOMM5 expression shows unfavorable associations in ACC, UVM, KICH, LIHC, KIRP and MESO. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TOMM5 RNA expression.
This table summarizes TOMM5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TOMM5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TOMM5 shows lower tumor expression in THCA and higher tumor expression in COAD, BLCA, LIHC, HNSC and STAD. The COAD box plot shows higher TOMM5 RNA expression in tumor versus normal tissue (log2 FC = +1.061, t-test p < 0.001).
This table shows molecular features associated with TOMM5 in patient tissues and cancer cell lines. In patient samples, TOMM5 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, TOMM5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Lymphoma.
